Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed data in a late-stage pulmonary fibrosis trial; Revolution Medicines’ newly approved pancreatic cancer drug works better for patients with certain mutations; and Caribou Biosciences may be on its way out.
While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.
The first-time CEO says her own sponsors took chances on her—and that industry leaders need to do the same to rebuild momentum for gender equity.
While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.
While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analysts say that outcome is now “less likely.”
Roche has gained access to a genetic obesity approach from China’s Rona Therapeutics for up to $100 million in upfront and near-term payments.
Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
After Pfizer’s venture arm co-led Enodia Therapeutics’ $25 million seed round in January, the pharma has signed up to collaborate with the biotech on small-molecule drugs to eliminate pathogenic proteins where they’re being made.
Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.